Budosenid Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report

Budosenid Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report

Author Info

Corresponding Author
El Ali Ziad
Department of Medical Oncology, IRIS Hospitals South, Brussels, Belgium

A B S T R A C T

Merkel cell carcinoma is a rare and highly agressive primary cutaneous cancer with epithelial and neuroendocrine features. Currently, for stage IV disease, up-front immunotherapy with check-point inhibitors, anti PD-L1 and anti PD-1, is recommanded. We report the case of a patient who was treated with Avelumab for a metastatic Merkel cell carcinoma. He presented a treatment induced grade II immune colitis, treated successfully with oral Budesonid, a synthetic steroid with high topical anti-inflammatory activity, minimal systemic absorption, and fewer side effects.

Article Info

Article Type
Case Report
Publication history
Received: Wed 14, Aug 2019
Accepted: Mon 23, Sep 2019
Published: Thu 24, Oct 2019
Copyright
© 2023 El Ali Ziad. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2019.05.04